Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) may be associated with rhabdomyolysis, a severe, sometimes

Read more ›

Share
Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

Childhood brain tumors: Genetic variability amenable to individualized therapy approaches

October  02, 2017 – Seemingly incurable childhood brain tumor is one of the most devastating clinical diagnosis a young patient and her/his family can get. For many, the associated sufferance is close to unbearable. A better understanding of the underlying biology and genetics of these tumors is desperately needed in order

Read more ›

Share
Posted in Genetic Background, In The Press, Pediatrics, Personalized Medicine, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , , ,

Obeticholic Acid (Ocaliva): Is there a serious drug safety problem?

September 30, 2017 – Obeticholic acid (Ocaliva) was approved by the American Food & Drug Administration (FDA) in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adult  patients with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate

Read more ›

Share
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
Tags: , , , ,

The first gene therapy FDA approved in the US

September 3, 2017 – For a very first time, the American Food & Drug Administration (FDA) has approved a gene therapy for the United States (US) in that it approved CAR T-cell therapy to treat certain children and young adults with B-cell acute lymphoblastic leukemia (B-cell ALL). To that end, the

Read more ›

Share
Posted in Gene Therapy, New Drug Approval, Personalized Medicine, Regulatory Approval, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , , , ,

Pembrolizumab (Keytruda): Clinical trials on hold

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of

Read more ›

Share
Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , , ,

Chagas disease: First time approval of a treatment in the US

August 31, 2017 – For the very first time, the American Food & Drug Administration (FDA) granted approval for a treatment of Chagas disease in the the United States. Chagas disease, or American trypanosomiasis, is a parasitic infection caused by Trypanosoma cruzi and can be transmitted through different routes, including contact

Read more ›

Share
Posted in New Drug Approval, Thasso Post, Theragenomic Medicine
Tags: , , , , ,

Synthetic cannabinoids unauthorized: Brainfreeze

August 26, 2017 – Health Canada is advising Canadians of unauthorized products called Brainfreeze Potpourri or Brainfreeze Herbal Incense that are labeled as herbal products and contain synthetic cannabinoids. This product is being sold in speciality tobacco stores and head shops in Edmonton, Alberta, and may also be available for

Read more ›

Share
Posted in Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , ,

Happy but blind: A role for erectile dysfunction (ED) drugs

August 26, 2017 – The erectile dysfunction (ED) drugs Tadalafil (Cialis), Vardenafil (Levitra), and even more so Sildenafil (Viagra) have previously been associated with a type of sudden vision loss called Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). According to a recent medical study, which is consistent with some earlier medical research,

Read more ›

Share
Posted in Adverse Drug Reaction [ADR], Genetic Predisposition, Regulatory Announcement, Thasso Post, Theragenomic Medicine
Tags: , , , , , ,

Besponsa: Is this really a viable new treatment for ALL?

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, the National Cancer Institute estimates that approximately 5,970 people will

Read more ›

Share
Posted in New Drug Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , , , ,

Body shop: First repair of single-gene mutation in human embryos

August 07, 2017 – Humans become reparable like a broken car in the body shop: For the first time, scientists have corrected a disease-causing mutation in early stage human embryos with gene editing (or genome editing). By doing so, researchers  repaired in these early stage human embryos the genetic/molecular defect

Read more ›

Share
Posted in Allelic Variant, Genetic Predisposition, Genetic Susceptibility, In The Press, Personalized Medicine, Rare Diseases, Thasso Post, Theragenomic Medicine
Tags: , , , , , , , , ,

thasso: conditions

thasso post: subscribe

By signing up, you agree to our Terms of Service and Privacy Policy.

thasso post: magazine

View my Flipboard Magazine.

thasso: follow us

Facebooktwittergoogle_pluslinkedinrssyoutubeby feather

thasso: chat

You must be a registered user to participate in this chat.

thasso: tweets

thasso: categories

thasso: archives